{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T04:45:12Z","timestamp":1775537112731,"version":"3.50.1"},"reference-count":65,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:00Z","timestamp":1623283200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vox Sanguinis"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Objectives<\/jats:title>\n                    <jats:p>The use of immunoglobulin (IG) solutions as an immunomodulatory therapy in certain neurological conditions has become an established modality and represents a significant proportion of total IG use. The estimation of the evidence\u2010based potential demand designated as the latent therapeutic demand (LTD) for IG in these diseases is required for adequate planning of the plasma supply required to manufacture the product.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>The diseases studied included chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain\u2013Barr\u00e9 syndrome (GBS) and multifocal motor neuropathy (MMN). The LTD for IG was assessed using a decision analysis model, using Microsoft Excel. The model analysed the epidemiological and clinical factors contributing to IG usage. One\u2010way sensitivity analysis and probabilistic sensitivity analysis derived the LTD in grams per 1000 inhabitants. The key variables included the treatment schedule and the prevalence of the disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The model estimates that an average annual IG demand and standard deviation for CIDP, GBS and MMN in the United States is 83.05\u2009\u00b1\u200924.5, 6.1\u2009\u00b1\u20093.2 and 36.1\u2009\u00b1\u200925.5\u00a0g\/1000 inhabitants, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Together with previous work on the LTD for IG in immunodeficiencies, these results indicate that current IG usage reflects the estimated LTD for the main indications for IG in the United States The wide range of LTD found in all these studies emphasizes the need for more precise assessment of the underlying variables, particularly disease prevalence and dosage. Further studies on other indications such as secondary immunodeficiencies will augment these results and will assist in guiding demand planning for IG use and plasma collection in the United States and inform blood policy in other countries.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/vox.13134","type":"journal-article","created":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T23:22:25Z","timestamp":1623367345000},"page":"208-219","source":"Crossref","is-referenced-by-count":6,"title":["Estimation of the latent therapeutic demand for immunoglobulin therapies in autoimmune neuropathies in the United States"],"prefix":"10.1111","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0804-7463","authenticated-orcid":false,"given":"Albert","family":"Farrugia","sequence":"first","affiliation":[{"name":"Faculty of Medicine and Health Sciences University of Western Australia  Perth Western Australia Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megha","family":"Bansal","sequence":"additional","affiliation":[{"name":"Private Consultant, Health Economics and Outcomes Research"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Marjanovic","sequence":"additional","affiliation":[{"name":"Private Consultant in Neurology  Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,6,10]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-68038-5_8"},{"key":"e_1_2_7_3_1","unstructured":"Grifols.Investor and Analyst Meeting 2019 [Internet]; 2019.https:\/\/www.grifols.com\/documents\/51507592\/90066043\/IAD+2019+Grifols.pdf\/e2505992\u20101b9c\u20104168\u20109f08\u2010b68a75170c4c Accessed February 12 2020"},{"key":"e_1_2_7_4_1","unstructured":"Center for Biologics Evaluation and Research. Information About Immune Globulin (Human) Product Shortage. FDA [Internet]; 2019.http:\/\/www.fda.gov\/vaccines\u2010blood\u2010biologics\/safety\u2010availability\u2010biologics\/information\u2010about\u2010immune\u2010globulin\u2010human\u2010product\u2010shortage Accessed February 2 2020"},{"key":"e_1_2_7_5_1","unstructured":"LoftusP.Drug shortage leaves patients without immune\u2010disorder treatment.Wall Street Journal; 2019.https:\/\/www.wsj.com\/articles\/drug-shortage-leaves-patients-without-immune-disorder-treatment-11565343023 Accessed December 2 2020"},{"key":"e_1_2_7_6_1","first-page":"449","article-title":"The growing importance of achieving national self\u2010sufficiency in immunoglobulin in Italy. The emergence of a national imperative","volume":"17","author":"Farrugia A","year":"2019","journal-title":"Blood Transfus"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-013-9975-1"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12651"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756285612457215"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/119.4.1055"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.NT.0000338397.95341.06"},{"key":"e_1_2_7_12_1","unstructured":"Center for Biologics Evaluation and Research.Immune Globulins. FDA; 2020.https:\/\/www.fda.gov\/vaccines-blood-biologics\/approved-blood-products\/immune-globulins Accessed December 2 2020"},{"key":"e_1_2_7_13_1","unstructured":"European Medicines Agency.Guideline on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIg) EMA\/CHMP\/BPWP\/94033\/2007 rev. 4; 2020.https:\/\/www.ema.europa.eu\/en\/documents\/scientific\u2010guideline\/draft\u2010guideline\u2010clinical\u2010investigation\u2010human\u2010normal\u2010immunoglobulin\u2010intravenous\u2010administration\u2010ivig_en\u20101.pdf"},{"key":"e_1_2_7_14_1","unstructured":"European Medicines Agency.Guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg); 2018.https:\/\/www.ema.europa.eu\/en\/documents\/scientific\u2010guideline\/guideline\u2010core\u2010smpc\u2010human\u2010normal\u2010immunoglobulin\u2010intravenous\u2010administration\u2010ivig\u2010rev\u20105_en.pdf"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0b013e3181f3dbbf"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-010-9407-4"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31824de293"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awf193"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00841.x"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70329-0"},{"key":"e_1_2_7_21_1","unstructured":"Australian National Blood Authority.Chronic inflammatory demyelinating polyneuropathy \u2010 dosage of immunoglobulin; 2014Available fromhttps:\/\/www.blood.gov.au\/pubs\/ivig\/conditions-for-which-IVIg-has-an-established-therapeutic-role.html#cdn-03 Accessed February 12 2020"},{"key":"e_1_2_7_22_1","unstructured":"Australian National Blood Authority.Multifocal motor neuropathy \u2013 Dosage of immunoglobulin; 2014."},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-013-0269-y"},{"key":"e_1_2_7_24_1","first-page":"717","volume-title":"Microsoft Excel data analysis and business modeling","author":"Winston W","year":"2019"},{"key":"e_1_2_7_25_1","unstructured":"Thakur M.TornadoChart in Excel | Step by Step Examples to Create Tornado Chart [Internet].WallStreetMojo; 2019.https:\/\/www.wallstreetmojo.com\/tornado-chart-in-excel\/ Accessed April 14 2021"},{"key":"e_1_2_7_26_1","unstructured":"Cynthia Counter.Probability histogram with Excel simple [Internet]; 2015.https:\/\/www.youtube.com\/watch?v=LOA3kKOnUH0 Accessed April 14 2021"},{"key":"e_1_2_7_27_1","unstructured":"FarrugiaA BansalM.Model construction \u2010 Latent Therapeutic Demand for Immunoglobulin in neuropathies [Internet]. 2021.https:\/\/www.researchgate.net\/project\/Latent-Therapeutic-Demand-for-Immunoglobulin-in-neuropathies Accessed April 18 2021"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181aaea47"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.66.5.677"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8249(199912)46:6<910::AID-ANA14>3.0.CO;2-2"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-1331.2001.00187.x"},{"key":"e_1_2_7_32_1","volume-title":"Guilliann Barre syndrome","author":"US National Library of Medicine","year":"2011"},{"key":"e_1_2_7_33_1","first-page":"567","article-title":"Multifocal motor neuropathy: A review of pathogenesis, diagnosis, and treatment","volume":"10","author":"Lawson VH","year":"2014","journal-title":"Neuropsychiatr Dis Treat"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2006.00792.x"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-009-0043-9"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23843"},{"key":"e_1_2_7_37_1","unstructured":"National Blood Authority of Australia.Criteria for clinical use of immunoglobulin in Australia; 2012https:\/\/www.criteria.blood.gov.au\/CheckEligibility Accessed October 7 2019"},{"key":"e_1_2_7_38_1","first-page":"CD001797","article-title":"Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"12","author":"Eftimov F","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2009.02930.x"},{"key":"e_1_2_7_40_1","unstructured":"National Blood Authority (Australia).Criteria for the clinical use of intravenous immunoglobulin in Australia; 2012."},{"key":"e_1_2_7_41_1","unstructured":"Van den BergLH.The Long Term Treatment of Multifocal Motor Neuropathy with Intravenous Immunoglobulin; 2014. (European Neurological Review)."},{"key":"e_1_2_7_42_1","unstructured":"Agency for Health care Research and Quality.HCUP\u2010US NIS overview; 2020.https:\/\/www.hcup-us.ahrq.gov\/nisoverview.jsp Accessed December 8 2020"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.62.4.391"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2009.02568.x"},{"key":"e_1_2_7_45_1","first-page":"1","article-title":"Anthropometric reference data for children and adults: United States, 2007\u20101010.","volume":"11","author":"Fryar GO","year":"2012","journal-title":"Vital Health Stat"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.orp.2018.09.002"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12444"},{"key":"e_1_2_7_48_1","first-page":"223","article-title":"A phase 3 multicenter, prospective, open\u2010label efficacy and safety study of immune globulin (human) 10% Caprylate\/chromatography purified in patients with myasthenia gravis exacerbations","volume":"81","author":"Karelis G","year":"2019","journal-title":"ENE"},{"key":"e_1_2_7_49_1","doi-asserted-by":"crossref","unstructured":"GajdosP ChevretS ToykaKV.Intravenous immunoglobulin for myasthenia gravis. Cochrane Database of Systematic Reviews; 2012.https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD002277.pub4\/full Accessed April 16 2021","DOI":"10.1002\/14651858.CD002277.pub4"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-015-0398-y"},{"key":"e_1_2_7_51_1","first-page":"161","article-title":"Incidence and prevalence of chronic inflammatory demyelinating polyradiculoneuropathy: A systematic review and meta\u2010analysis","volume":"52","author":"Broers MC","year":"2019","journal-title":"NED"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2016.05.007"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2007.128132"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2020.02.009"},{"key":"e_1_2_7_55_1","unstructured":"Australian Medical Services Advisory Committe C of A. Immunoglobulin for chronic Inflammatory Demyelinating Polyneuropathy (CIDP). MSAC Application 1564 Assessment Report. [Internet]. 2019 Nov. Report No.: MSAC application no. 1564.http:\/\/www.msac.gov.au\/internet\/msac\/publishing.nsf\/Content\/2B740EDAE80B75DFCA25837E00096D86\/$File\/1564_MSAC_Assessment%20Report_Redacted.pdf"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.41.5.617"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21206"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001833"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2019.116497"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25409"},{"key":"e_1_2_7_61_1","unstructured":"BehringCSL.Immune Globulin Subcutaneous (Human) (IGSC) 20% Liquid Hizentra \u2010 Package insert; 2018"},{"key":"e_1_2_7_62_1","unstructured":"Government of Canada PS and PC. Protecting access to immune globulins for Canadians: Final report of the expert panel on immune globulin product supply and related impacts in Canada; 2018.http:\/\/publications.gc.ca\/site\/eng\/9.854785\/publication.html. Accessed October 8 2019"},{"key":"e_1_2_7_63_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00629"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2013.09.014"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000696"},{"key":"e_1_2_7_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.07.015"}],"container-title":["Vox Sanguinis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.13134","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/vox.13134","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.13134","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T11:00:29Z","timestamp":1692615629000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vox.13134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,10]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1111\/vox.13134"],"URL":"https:\/\/doi.org\/10.1111\/vox.13134","archive":["Portico"],"relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.05.27.20114579","asserted-by":"object"}]},"ISSN":["0042-9007","1423-0410"],"issn-type":[{"value":"0042-9007","type":"print"},{"value":"1423-0410","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,10]]}}}